Polity11 July 20264 min read
Health Ministry removes Schedule K exemption for high-alcohol drugs
The Union Ministry of Health and Family Welfare has amended the Drugs Rules, 1945 in two ways. It removed the Schedule K exemption from licensing for formulations containing more than 12% volume per volume (v/v) ethyl alcohol in quantities above 30 millilitres. It also amended Rule 43A to notify Navi Mumbai Airport as an authorised entry point for drug imports.
What changes for high-alcohol formulations
Schedule K lists certain drugs exempted from some provisions of the Rules, subject to specified conditions. It eases the sale and distribution of certain categories of medicines where strict licensing is not considered necessary.
Formulations above the 12% v/v and 30 ml thresholds no longer fall under that exemption. Such products must now obtain the requisite licences under the Drugs and Cosmetics Act, 1940. The amendment is expected to strengthen oversight of medicinal products containing alcohol and to ensure they are supplied only through the regulated pharmaceutical supply chain.
Why the exemption was removed
Before the amendment in July 2026, some medicinal preparations containing ethyl alcohol were being diverted and misused as intoxicating substitutes. State governments had flagged the issue and asked for urgent intervention.
The change also sits alongside wider concerns about drug quality and compliance. Substandard or spurious drugs can cause treatment failure and fatal drug-induced toxicities. Unregulated over-the-counter (OTC) dispensing of powerful antimicrobials aggravates antimicrobial resistance. As a major global supplier of generic medicines, India also needs strict compliance to pass international audits by agencies such as the USFDA.
Navi Mumbai Airport added as an import point
The notification permitting drug imports through the newly inaugurated Navi Mumbai Airport was issued under the 1940 Act after consultation with the Drugs Technical Advisory Board (DTAB), a statutory body that advises governments on technical matters related to the regulation of drugs and cosmetics.
With the amendment to Rule 43A, the number of approved road, rail, sea and air entry points rises to 42. The ministry expects smoother and faster movement of pharmaceutical consignments. Importers get an additional route, which reduces dependence on existing entry points. The ministry said the measure seeks to improve trade facilitation and Ease of Doing Business while keeping regulatory oversight of imported drugs.
How drug regulation is organised
The Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General (India), is the central authority for the quality of drugs marketed in the country under the 1940 Act and its Rules. Import, manufacture, distribution and sale of drugs, cosmetics and medical devices are regulated under the Act and the Rules made under it: the Drugs Rules, 1945, Medical Devices Rules, 2017, New Drugs and Clinical Trials Rules, 2019 and Cosmetics Rules, 2020.
The National Pharmaceutical Pricing Authority (NPPA) fixes and revises drug prices under the Drugs (Prices Control) Order (DPCO), 2013, monitors compliance and ensures the availability of essential medicines. The Indian Pharmacopoeia Commission oversees publication of the Indian Pharmacopoeia, which prescribes standards of identity, purity and strength for medicines.
The work is divided between the Centre and the States. Manufacture, sale and distribution are controlled through licensing and inspection by State Licensing Authorities appointed by State Governments, while imported drugs are controlled by the Central Government through the CDSCO. The State Health Regulatory Excellence Index (SHRESTH) is a national initiative to benchmark and strengthen state drug regulatory systems through a data-driven framework.
Contamination and quality lapses point to weaknesses in adherence to manufacturing standards. Multiple regulatory authorities and varying enforcement standards create inconsistencies in monitoring, and widespread self-medication raises the risk of unsafe use of medicines. Because regulation is a shared responsibility of the Union and State governments, many State drug control departments face shortages of inspectors, laboratories and technical personnel.